Leadership
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.
Pfenex founder and chief business officer Patrick Lucy has left the company to join Lykan Bioscience. Meanwhile, Samsung Biologics has announced the appointment of a new president and CEO, as the Australian generics and biosimilars association appoints a new chair.
In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla libero felis, cursus nec felis id, pretium accumsan tellus.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.
With a clear focus on complex products, Lupin sets out its launch plans for the year ahead, while battling ongoing litigation over some of its generics.
Sandoz has delivered the first denosumab biosimilar launch in Canada, introducing its Jubbonti and Wyost rivals to Amgen’s Prolia and Xgeva.
Sandoz has revealed senior management changes and details of a restructuring plan to drive efficiencies, as the firm unveiled positive results for the second quarter of 2024 that saw biosimilars continue to drive solid growth for the company.
Dr Reddy’s has provided key expected dates for movement on its slate of pending biosimilars, as it continues to drive towards a meaningful impact from biosimilars in key markets in 2026/27.